Xp11 translocation renal cell carcinoma: Delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy

被引:44
作者
Rais-Bahrami, Soroush
Drabick, Joseph J.
De Marzo, Angelo M.
Hicks, Jessica
Ho, Clement
Caroe, Alan E.
Argani, Pedram
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[3] Milton S Hershey Med Ctr, Dept Med, Hershey, PA USA
[4] York Oncol Associates, York, N Yorkshire, England
[5] York Hosp, Dept Pathol, York, PA USA
关键词
D O I
10.1016/j.urology.2007.03.037
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A recently described subtype of renal cell carcinoma (RCC) bearing chromosome translocations involving a breakpoint at Xp11 and resulting in gene fusions involving the TFE3 transcription factor gene often presents in the pediatric population. Herein we describe an Xp11 translocation RCC associated with prior exposure to cytotoxic chemotherapy, which massively recurred and led to the patient's death 17 years later. This case highlights the association of these RCCs with prior chemotherapy exposure, the tendency of these RCCs to recur late, their unusual pattern of metastases, and the utility of TFE3 immunohistochemistry in confirming their diagnosis in archival pathologic specimens.
引用
收藏
页码:178.e3 / 178.e6
页数:4
相关论文
共 9 条
[1]   Translocation carcinomas of the kidney after chemotherapy in childhood [J].
Argani, P ;
Laé, M ;
Ballard, ET ;
Amin, M ;
Manivel, C ;
Hutchinson, B ;
Reuter, VE ;
Ladanyi, M .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) :1529-1534
[2]   Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions -: A sensitive and specific immunohistochemical assay [J].
Argani, P ;
Lal, P ;
Hutchinson, B ;
Lui, MY ;
Reuter, VE ;
Ladanyi, M .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (06) :750-761
[3]   Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma -: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents [J].
Argani, P ;
Antonescu, CR ;
Illei, PB ;
Lui, MY ;
Timmons, CF ;
Newbury, R ;
Reuter, VE ;
Garvin, AJ ;
Perez-Atayde, AR ;
Fletcher, JA ;
Beckwith, JB ;
Bridge, JA ;
Ladanyi, M .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (01) :179-192
[4]   The evolving story of renal translocation carcinomas [J].
Argani, Pedram ;
Ladanyi, Marc .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (03) :332-334
[5]  
Dal Cin P, 1998, CANCER GENET CYTOGEN, V101, P58
[6]   Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma [J].
Geller, JI ;
Dome, JS .
CANCER, 2004, 101 (07) :1575-1583
[7]   Two new cases of papillary renal cell carcinoma with t(X;1)(p11;q21) in females [J].
Pérot, C ;
Bougaran, J ;
Boccon-Gibod, L ;
Störkel, S ;
Leverger, G ;
van den Akker, J ;
Taillemite, JL ;
Couturier, J .
CANCER GENETICS AND CYTOGENETICS, 1999, 110 (01) :54-56
[8]   Pediatric renal cell carcinoma - Clinical, pathologic, and molecular abnormalities associated with the members of the MiT transcription factor family [J].
Ramphal, Raveena ;
Pappo, Alberto ;
Zielenska, Maria ;
Grant, Ronald ;
Ngan, Bo-Yee .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 126 (03) :349-364
[9]   TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition [J].
Tsuda, Masumi ;
Davis, Ian J. ;
Argani, Pedram ;
Shukla, Neerav ;
McGill, Gael G. ;
Nagai, Makoto ;
Saito, Tsuyoshi ;
Lae, Marick ;
Fisher, David E. ;
Ladanyi, Marc .
CANCER RESEARCH, 2007, 67 (03) :919-929